MedTrace Logo

Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC

NCT02799862 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 408

Last updated 2021-10-06

No results posted yet for this study

Summary

This is a single-arm non-interventional study (NIS) to evaluate the effectiveness, safety and quality of life (QoL) in patients with advanced NSCLC receiving the combination of nab-paclitaxel and carboplatin as first line palliative therapy in a real life setting.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.

DRUG

Carboplatin

Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.

Sponsors & Collaborators

Principal Investigators

  • Tobias Dechow, Prof. Dr. · Oncology Ravensburg

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-29
Primary Completion
2019-12-07
Completion
2021-06-06

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02799862 on ClinicalTrials.gov